The need for a wonder drug antibiotic that is impervious to resistance is so great that IMO the only possible reason is that so very few people, even in the medical field, are aware of how powerful and effective evidence to date show it to be.
Overlooking this drug makes me question how many really sharp investors and analysts follow clinical trials progress and most appear to come to the table (or even know about the table) only at the very finish of the trials progress.
Can't think of a better example of DD and knowing what you own than CTIX and Brilacidin in particular. Who is screwed up regarding Brilacidin, we investors or the market? Since our beliefs are backed up by empirical data, the only possible answer can be the market and I fully agree that too many people give "the market" far too much credit. I like Brilacidin's chances for success and have no qualms that the screwy market is making a major oversight regarding its value.
Market Data 
Markets 
AI
